These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1605 related articles for article (PubMed ID: 30333516)

  • 1. NTRK fusion-positive cancers and TRK inhibitor therapy.
    Cocco E; Scaltriti M; Drilon A
    Nat Rev Clin Oncol; 2018 Dec; 15(12):731-747. PubMed ID: 30333516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing algorithm for identification of patients with TRK fusion cancer.
    Penault-Llorca F; Rudzinski ER; Sepulveda AR
    J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
    Farago AF; Demetri GD
    Future Oncol; 2020 Mar; 16(9):417-425. PubMed ID: 32129093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
    Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loxo TRK inhibitor data wows oncologists.
    Dolgin E
    Nat Biotechnol; 2017 Aug; 35(8):694-695. PubMed ID: 28787403
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting TRK family proteins in cancer.
    Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
    Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving role of entrectinib in treatment of
    Chawla N; Bui NQ; Seetharam M
    Future Oncol; 2021 Aug; 17(22):2835-2846. PubMed ID: 33896226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors.
    Kim EE; Park CK; Kim SK; Phi JH; Paek SH; Choi JY; Kang HJ; Lee JH; Won JK; Yun H; Park SH
    Acta Neuropathol Commun; 2024 Jul; 12(1):118. PubMed ID: 39014476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib.
    Rudzinski ER; Hechtman J; Roy-Chowdhuri S; Rudolph M; Lockwood CM; Silvertown J; Wierzbinska J; Shen K; Norenberg R; Nogai H; Hong DS; Drilon A; Laetsch TW
    Cancer Genet; 2022 Jan; 260-261():46-52. PubMed ID: 34929613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening.
    Albert CM; Davis JL; Federman N; Casanova M; Laetsch TW
    J Clin Oncol; 2019 Feb; 37(6):513-524. PubMed ID: 30592640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.
    Taylor J; Pavlick D; Yoshimi A; Marcelus C; Chung SS; Hechtman JF; Benayed R; Cocco E; Durham BH; Bitner L; Inoue D; Chung YR; Mullaney K; Watts JM; Diamond EL; Albacker LA; Mughal TI; Ebata K; Tuch BB; Ku N; Scaltriti M; Roshal M; Arcila M; Ali S; Hyman DM; Park JH; Abdel-Wahab O
    J Clin Invest; 2018 Aug; 128(9):3819-3825. PubMed ID: 29920189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Larotrectinib in NTRK-Rearranged Solid Tumors
    Wilson FH; Herbst RS
    Biochemistry; 2019 Mar; 58(12):1555-1557. PubMed ID: 30865435
    [No Abstract]   [Full Text] [Related]  

  • 14. A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib.
    Caldwell KJ; De La Cuesta E; Morin C; Pappo A; Helmig S
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28330. PubMed ID: 32452122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.
    Rolfo C; Drilon A; Hong D; McCoach C; Dowlati A; Lin JJ; Russo A; Schram AM; Liu SV; Nieva JJ; Nguyen T; Eshaghian S; Morse M; Gettinger S; Mobayed M; Goldberg S; Araujo-Mino E; Vidula N; Bardia A; Subramanian J; Sashital D; Stinchcombe T; Kiedrowski L; Price K; Gandara DR
    Br J Cancer; 2022 Feb; 126(3):514-520. PubMed ID: 34480094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?].
    Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T
    Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A
    Ann Oncol; 2019 Nov; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and treatment patterns of patients with
    Willis C; Au T; Hejazi A; Griswold C; Schabath MB; Thompson J; Malhotra J; Federman N; Ko G; Appukkuttan S; Warnock N; Kong SX; Hocum B; Brixner D; Stenehjem D
    J Manag Care Spec Pharm; 2024 Jul; 30(7):672-683. PubMed ID: 38950155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRK Inhibitors: Clinical Development of Larotrectinib.
    Bhangoo MS; Sigal D
    Curr Oncol Rep; 2019 Feb; 21(2):14. PubMed ID: 30715603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion].
    Delaye M; Rodrigues M
    Bull Cancer; 2020 Nov; 107(11):1085-1086. PubMed ID: 33169692
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 81.